{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:19:13Z","timestamp":1762492753755,"version":"build-2065373602"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijcha.2023.101267","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T08:21:54Z","timestamp":1694161314000},"page":"101267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacotherapy in patients with vasomotor disorders"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1515-9623","authenticated-orcid":false,"given":"C.K.M.","family":"Boerhout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.G.T.","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.P.","family":"van de Hoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.M.","family":"Beijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ijcha.2023.101267_b0005","article-title":"Global epidemiology of ischemic heart disease: results from the global burden of disease study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ijcha.2023.101267_b0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0907272","article-title":"Low diagnostic yield of elective coronary angiography","author":"Patel","year":"2010","journal-title":"New Eng. J. Med."},{"issue":"12","key":"10.1016\/j.ijcha.2023.101267_b0015","doi-asserted-by":"crossref","first-page":"e008126","DOI":"10.1161\/CIRCINTERVENTIONS.119.008126","article-title":"Ischemia and no obstructive coronary artery disease: prevalence and correlates of coronary vasomotion disorders","volume":"12","author":"Ford","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"23_Part_A","key":"10.1016\/j.ijcha.2023.101267_b0020","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","article-title":"Stratified medical therapy using invasive coronary function testing in angina","volume":"72","author":"Ford","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2023.101267_b0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2017.08.068","article-title":"International standardization of diagnostic criteria for microvascular angina","volume":"250","author":"Ong","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"16","key":"10.1016\/j.ijcha.2023.101267_b0030","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1161\/CIRCULATIONAHA.111.037283","article-title":"Mechanisms of coronary artery spasm","volume":"124","author":"Lanza","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0035","doi-asserted-by":"crossref","DOI":"10.1097\/00041433-200108000-00003","article-title":"Endothelial function and coronary artery disease","volume":"12","author":"Kinlay","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jjcc.2008.01.001","article-title":"Coronary artery spasm\u2014Clinical features, diagnosis, pathogenesis, and treatment","volume":"51","author":"Yasue","year":"2008","journal-title":"J. Cardiol."},{"issue":"15","key":"10.1016\/j.ijcha.2023.101267_b0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4244\/EIJ-D-21-00402","article-title":"Principles and pitfalls in coronary vasomotor function testing","volume":"17","author":"Feenstra","year":"2022","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9149(78)90810-X","article-title":"Ergonovine maleate provocative test for coronary arterial spasm","volume":"41","author":"Heupler","year":"1978","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcha.2023.101267_b0055","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/01.CIR.79.5.1043","article-title":"Direct vasoconstriction and endothelium-dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries","volume":"79","author":"Hodgson","year":"1989","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ijcha.2023.101267_b0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","article-title":"Coronary microvascular dysfunction: an update","volume":"35","author":"Crea","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2023.101267_b0065","doi-asserted-by":"crossref","DOI":"10.1007\/s12471-020-01451-9","article-title":"Ischaemia with no obstructive coronary arteries","author":"Konst","year":"2020","journal-title":"Neth. Hear. J."},{"issue":"20","key":"10.1016\/j.ijcha.2023.101267_b0070","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.jacc.2020.03.051","article-title":"Physiological stratification of patients with angina due to coronary microvascular dysfunction","volume":"75","author":"Haseeb","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcha.2023.101267_b0075","doi-asserted-by":"crossref","first-page":"e012017","DOI":"10.1161\/CIRCINTERVENTIONS.122.012017","article-title":"Presence of coronary endothelial dysfunction, coronary vasospasm, and adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstructive coronary arteries","volume":"15","author":"Feenstra","year":"2022","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1540-8183.2010.00598.x","article-title":"An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute\u2013sponsored Women\u2019s Ischemia Syndrome Evaluation (WISE)","volume":"23","author":"Khuddus","year":"2010","journal-title":"J. Interv. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0085","first-page":"51","article-title":"Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults","volume":"52","author":"Menyar","year":"2006","journal-title":"J. Postgrad. Med."},{"issue":"3","key":"10.1016\/j.ijcha.2023.101267_b0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.ijcha.2023.101267_b0095","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jcin.2014.12.249","article-title":"The 24-month prognosis of patients with positive or intermediate results in the intracoronary ergonovine provocation test","volume":"8","author":"Shin","year":"2015","journal-title":"J. Am. Coll. Cardiol. Intv."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0002-8703(83)90548-3","article-title":"Effect of aspirin in large doses on attacks of variant angina","volume":"105","author":"Miwa","year":"1983","journal-title":"Am. Heart J."},{"issue":"14","key":"10.1016\/j.ijcha.2023.101267_b0105","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM198304073081402","article-title":"Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients","volume":"308","author":"Weksler","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcha.2023.101267_b0110","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ijcard.2012.11.010","article-title":"Clinical outcomes of low-dose aspirin administration in patients with variant angina pectoris","volume":"167","author":"Kim","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-54390-w","article-title":"Clopidogrel plus aspirin use is associated with worse long-term outcomes, but aspirin use alone is safe in patients with vasospastic angina: results from the VA-Korea registry, a prospective multi-center cohort","volume":"9","author":"Cho","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.ijcha.2023.101267_b0120","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1161\/CIRCULATIONAHA.114.012636","article-title":"Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease","volume":"131","author":"Lee","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/FJC.0b013e31817d4507","article-title":"Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study","volume":"52","author":"Tani","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"18","key":"10.1016\/j.ijcha.2023.101267_b0130","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.12.049","article-title":"Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers","volume":"51","author":"Yasue","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcha.2023.101267_b0135","doi-asserted-by":"crossref","first-page":"e003426","DOI":"10.1161\/JAHA.116.003426","article-title":"Impact of statin therapy on clinical outcome in patients with coronary spasm","volume":"5","author":"Ishii","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2023.101267_b0140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijcard.2016.08.229","article-title":"Impact of statin therapy on long-term clinical outcomes of vasospastic angina without significant stenosis: a propensity-score matched analysis","volume":"223","author":"Oh","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0145","doi-asserted-by":"crossref","first-page":"e0210498","DOI":"10.1371\/journal.pone.0210498","article-title":"Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service","volume":"14","author":"Park","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ijcha.2023.101267_b0150","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00380-020-01579-z","article-title":"Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study","volume":"35","author":"Seo","year":"2020","journal-title":"Heart Vessels"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/01.HYP.36.4.575","article-title":"Renin-angiotensin system blockade improves endothelial dysfunction in hypertension","volume":"36","author":"Goto","year":"2000","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0165","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","article-title":"Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis","volume":"37","author":"Dzau","year":"2001","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0170","doi-asserted-by":"crossref","first-page":"H1291","DOI":"10.1152\/ajpheart.00181.2007","article-title":"Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation","volume":"293","author":"Banes-Berceli","year":"2007","journal-title":"Am. J. Physiol. Circ. Physiol."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.21.4.631","article-title":"Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension","volume":"21","author":"Giugliano","year":"1998","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ijcha.2023.101267_b0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/10739680701410827","article-title":"Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease","volume":"14","author":"Higuchi","year":"2007","journal-title":"Microcirculation"},{"issue":"5","key":"10.1016\/j.ijcha.2023.101267_b0185","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/01.HYP.27.5.1031","article-title":"Improvement of coronary flow reserve after long-term therapy with enalapril","volume":"27","author":"Motz","year":"1996","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004872-199715020-00011","article-title":"Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy","volume":"15","author":"Rizzoni","year":"1997","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0195","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ahj.2011.07.011","article-title":"In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Hea","volume":"162","author":"Pauly","year":"2011","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/01.CIR.0000100722.34034.E4","article-title":"Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity","volume":"109","author":"Pizzi","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ijcha.2023.101267_b0205","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9149(02)02664-4","article-title":"Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X","volume":"90","author":"Chen","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000006768","article-title":"Therapeutic benefits of cilazapril in patients with syndrome X","volume":"89","author":"Nalbantgil","year":"1998","journal-title":"Cardiology"},{"issue":"7","key":"10.1016\/j.ijcha.2023.101267_b0215","doi-asserted-by":"crossref","first-page":"e003217","DOI":"10.1161\/JAHA.116.003217","article-title":"Impact of renin-angiotensin system inhibitors on long-term clinical outcomes of patients with coronary artery spasm","volume":"5","author":"Choi","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0220","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4037\/ajcc2004.13.4.350","article-title":"Prinzmetal\u2019s angina","volume":"13","author":"Keller","year":"2004","journal-title":"Am. J. Crit. Care"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.hlc.2006.11.003","article-title":"The mystery of coronary artery spasm","volume":"16","author":"Ajani","year":"2007","journal-title":"Hear Lung Circ."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0230","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/01.CIR.103.6.e30","article-title":"Ergonovine maleate and \u03b2-blockers for Prinzmetal\u2019s angina","volume":"103","author":"Cheng","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0235","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/heartjnl-2017-311446","article-title":"Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need","volume":"104","author":"Ford","year":"2018","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0240","first-page":"17","article-title":"Calcium channel blockers: differences between subclasses","volume":"7","author":"Frishman","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.57.1.137","article-title":"Nifedipine therapy for Prinzmetal\u2019s angina","volume":"57","author":"Muller","year":"1978","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ijcha.2023.101267_b0250","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM198006053022301","article-title":"Nifedipine therapy for coronary-artery spasm: experience in 127 patients","volume":"302","author":"Antman","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0255","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0033-0620(96)80015-6","article-title":"Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm","volume":"38","author":"Opie","year":"1996","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"5","key":"10.1016\/j.ijcha.2023.101267_b0260","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/030006057900700505","article-title":"A retrospective evaluation of nifedipine therapy in Prinzmetal\u2019s angina","volume":"7","author":"Battye","year":"1979","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ijcha.2023.101267_b0265","article-title":"Prognostic effects of calcium channel blockers in patients with vasospastic angina\u2013A meta-analysis","volume":"1007200817","author":"Nishigaki","year":"2010","journal-title":"Circ J"},{"issue":"3","key":"10.1016\/j.ijcha.2023.101267_b0270","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/0002-8703(82)90257-5","article-title":"Randomized withdrawal from nifedipine: placebo-controlled study in patients with coronary artery spasm","volume":"104","author":"Schick","year":"1982","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0275","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0735-1097(93)90310-W","article-title":"Randomized placebo-controlled trial of amlodipine in vasospastic angina","volume":"21","author":"Chahine","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.ijcha.2023.101267_b0280","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJM198104093041502","article-title":"A controlled trial of verapamil for Prinzmetal\u2019s variant angina","volume":"304","author":"Johnson","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0285","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1007747114386","article-title":"Vasomotion of coronary arteries: from nitrates to nitric oxide","volume":"13","author":"Tousoulis","year":"1999","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0290","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0002-8703(85)90495-8","article-title":"Isosorbide dinitrate and nifedipine in variant angina pectoris","volume":"110","author":"Conti","year":"1985","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/bjp.2008.263","article-title":"The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles","volume":"155","author":"Mayer","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcin.2021.10.003","article-title":"Acetylcholine Rechallenge","volume":"15","author":"Seitz","year":"2022","journal-title":"J. Am. Coll. Cardiol. Intv."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000370027","article-title":"Poor tolerance and limited effects of isosorbide-5-mononitrate in microvascular angina","volume":"130","author":"Wu","year":"2015","journal-title":"Cardiology"},{"issue":"21","key":"10.1016\/j.ijcha.2023.101267_b0310","doi-asserted-by":"crossref","first-page":"J18","DOI":"10.1016\/0002-9149(89)90200-2","article-title":"Nicorandil as a hybrid between nitrates and potassium channel activators","volume":"63","author":"Taira","year":"1989","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0315","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10557-016-6668-z","article-title":"Vasodilator therapy: nitrates and nicorandil","volume":"30","author":"Tarkin","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0320","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00005344-200006000-00014","article-title":"Effects of intravenous nicorandil on coronary circulation in humans: plasma concentration and action mechanism","volume":"35","author":"Nakae","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0325","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00005344-199510000-00006","article-title":"Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels","volume":"26","author":"Akai","year":"1995","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"37","key":"10.1016\/j.ijcha.2023.101267_b0330","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022167","article-title":"The effect of nicorandil in patients with cardiac syndrome X: a meta-analysis of randomized controlled trials","volume":"99","author":"Jia","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.ijcha.2023.101267_b0335","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2165\/00003088-199630050-00004","article-title":"Clinical pharmacokinetics of molsidomine","volume":"30","author":"Rosenkranz","year":"1996","journal-title":"Clin. Pharmacokinet."},{"issue":"05","key":"10.1016\/j.ijcha.2023.101267_b0340","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0037-1613904","article-title":"Influence of SIN-1 on platelet Ca2+ handling in patients with suspected coronary artery disease: ex vivo and in vitro studies","volume":"83","author":"Sang","year":"2000","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0345","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2004.12.018","article-title":"Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina","volume":"180","author":"Van Hove","year":"2005","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1253\/jcj.42.1","article-title":"Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs","volume":"42","author":"Yasue","year":"1978","journal-title":"Jpn. Circ. J."},{"issue":"9","key":"10.1016\/j.ijcha.2023.101267_b0355","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jama.1976.03270100018019","article-title":"\u03b1-Adrenoceptor-mediated coronary artery spasm","volume":"236","author":"Levene","year":"1976","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0360","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-8703(83)90525-2","article-title":"Prazosin therapy for refractory variant angina","volume":"105","author":"Tzivoni","year":"1983","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0365","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.CIR.67.6.1185","article-title":"Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial","volume":"67","author":"Winniford","year":"1983","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0370","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00877330","article-title":"Adrenergically mediated coronary vasoconstriction in patients with syndrome X","volume":"8","author":"Camici","year":"1994","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0375","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00005344-199910000-00012","article-title":"Effect of \u03b11-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X","volume":"34","author":"Rosen","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1085\/jgp.20028593","article-title":"Current-dependent block of rabbit sino-atrial node If channels by ivabradine","volume":"120","author":"Bucchi","year":"2002","journal-title":"J. Gen. Physiol."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0385","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3390\/molecules17044225","article-title":"HCN channels and heart rate","volume":"17","author":"Scicchitano","year":"2012","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0390","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2010.11.035","article-title":"Ivabradine improves coronary flow reserve in patients with stable coronary artery disease","volume":"215","author":"Skalidis","year":"2011","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0395","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2023.101267_b0400","first-page":"353","article-title":"Update on ranolazine in the management of angina","volume":"10","author":"Codolosa","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcha.2023.101267_b0405","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijcard.2014.12.055","article-title":"Ranolazine: drug overview and possible role in primary microvascular angina management","volume":"181","author":"Cattaneo","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0002-9149(03)00458-2","article-title":"Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris","volume":"92","author":"Watanabe","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"19","key":"10.1016\/j.ijcha.2023.101267_b0415","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/heartjnl-2014-305986","article-title":"A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina","volume":"100","author":"Shin","year":"2014","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0420","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins","volume":"333","author":"Levin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2023.101267_b0425","first-page":"S2","article-title":"Vascular biology of endothelin","volume":"32","author":"Schiffrin","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0430","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2007.06.004","article-title":"The importance of endothelin-1 for vascular dysfunction in cardiovascular disease","volume":"76","author":"B\u00f6hm","year":"2007","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0435","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.83.2.476","article-title":"Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris","volume":"83","author":"Toyo-oka","year":"1991","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0440","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000313365","article-title":"First report of the successful use of bosentan in refractory vasospastic angina","volume":"116","author":"Krishnan","year":"2010","journal-title":"Cardiology"},{"issue":"3","key":"10.1016\/j.ijcha.2023.101267_b0445","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2143\/AC.64.3.2038032","article-title":"Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm","volume":"64","author":"Vermeltfoort","year":"2009","journal-title":"Acta Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0450","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","volume":"2","author":"Greene","year":"2013","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.ijcha.2023.101267_b0455","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","article-title":"Soluble guanylate cyclase stimulators and their potential use: a patent review","volume":"31","author":"Sandner","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0460","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1469-7793.2000.t01-2-00177.x","article-title":"Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II","volume":"522","author":"Somlyo","year":"2000","journal-title":"J. Physiol."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0465","first-page":"1062","article-title":"Involvement of Rho-kinase in hypertensive vascular disease\u2014a novel therapeutic target in hypertension","volume":"15","author":"Mukai","year":"2001","journal-title":"FASEB J."},{"issue":"11","key":"10.1016\/j.ijcha.2023.101267_b0470","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.CIR.101.11.1319","article-title":"Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1\u03b2","volume":"101","author":"Kandabashi","year":"2000","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ijcha.2023.101267_b0475","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/hc1002.105938","article-title":"Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina","volume":"105","author":"Masumoto","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0480","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MCA.0b013e3282f3420c","article-title":"Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina","volume":"19","author":"Otsuka","year":"2008","journal-title":"Coron. Artery Dis."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0485","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0735-1097(02)02632-3","article-title":"Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm","volume":"41","author":"Mohri","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0490","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ahj.2010.03.024","article-title":"A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health\/National Heart, Lung, and Blood Institute\u2013sponsored Women\u2019","volume":"159","author":"Merz","year":"2010","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0495","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/0735-1097(89)90380-X","article-title":"Improved exercise capacity with acute aminophylline administration in patients with syndrome X","volume":"14","author":"Emdin","year":"1989","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcha.2023.101267_b0500","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0002-9149(88)91204-0","article-title":"Aminophylline termination of dipyridamole stress as a trigger of coronary vasospasm in variant angina","volume":"62","author":"Picano","year":"1988","journal-title":"Am. J. Cardiol."},{"issue":"3\u20134","key":"10.1016\/j.ijcha.2023.101267_b0505","first-page":"287","article-title":"Alteration of myocardial mechanics in marginal magnesium deficiency","volume":"15","author":"Nair","year":"2002","journal-title":"Magnes. Res."},{"issue":"11","key":"10.1016\/j.ijcha.2023.101267_b0510","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-9149(90)91375-G","article-title":"Magnesium deficiency detected by intravenous loading test in variant angina pectoris","volume":"65","author":"Goto","year":"1990","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0515","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF03029740","article-title":"Magnesium content of erythrocytes in patients with vasospastic angina","volume":"5","author":"Tanabe","year":"1991","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"10","key":"10.1016\/j.ijcha.2023.101267_b0520","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0002-9149(99)80665-1","article-title":"Comparison of frequency of magnesium deficiency in patients with vasospastic angina and fixed coronary artory disease","volume":"75","author":"Igawa","year":"1995","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0525","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0735-1097(96)00256-2","article-title":"Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina","volume":"28","author":"Satake","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0530","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1378\/chest.118.6.1690","article-title":"The preventive effect of magnesium on coronary spasm in patients with vasospastic angina","volume":"118","author":"Teragawa","year":"2000","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ijcha.2023.101267_b0535","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0735-1097(93)90357-7","article-title":"Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients","volume":"21","author":"Fleischhauer","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0540","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0735-1097(99)00548-3","article-title":"Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia","volume":"35","author":"Goodfellow","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2023.101267_b0545","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1161\/01.HYP.0000037969.41360.CC","article-title":"PPAR\u03b1 activator effects on Ang II\u2013induced vascular oxidative stress and inflammation","volume":"40","author":"Diep","year":"2002","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0550","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1476-5381.1994.tb16993.x","article-title":"NO-dependent and-independent elevation of plasma levels of insulin and glucose in rats by L-arginine","volume":"113","author":"Jun","year":"1994","journal-title":"Br. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.ijcha.2023.101267_b0555","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJM199405193302003","article-title":"Imipramine in patients with chest pain despite normal coronary angiograms","volume":"330","author":"Cannon","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcha.2023.101267_b0560","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/euhj.1997.0615","article-title":"Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms","volume":"19","author":"Cox","year":"1998","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcha.2023.101267_b0565","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ijcha.2023.101267_b0570","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/CIRCRESAHA.107.164384","article-title":"Peroxisome proliferator-activated receptor-\u03b3\u2013mediated effects in the vasculature","volume":"102","author":"Duan","year":"2008","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.ijcha.2023.101267_b0575","first-page":"1065","article-title":"Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance","volume":"44","author":"Leonardo","year":"1999","journal-title":"Cardiologia"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906723000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906723000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:14:57Z","timestamp":1762492497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906723000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":115,"alternative-id":["S2352906723000982"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2023.101267","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy in patients with vasomotor disorders","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2023.101267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101267"}}